Kodiak Sciences Stock Drops 7.8% - Should Investors Sell?

Shares of the biotech company fell sharply on Monday amid market volatility.

Mar. 30, 2026 at 7:58pm

Got story updates? Submit your updates here. ›

Shares of Kodiak Sciences Inc. (NASDAQ:KOD) dropped 7.8% on Monday, trading as low as $34.75 before closing at $34.10. Trading volume was down 13% from the average daily volume. The biotech company's stock has been on a rollercoaster ride in recent months as analysts weigh in on its prospects.

Why it matters

Kodiak Sciences is a clinical-stage biotech focused on developing novel therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema. Its lead drug candidate, KSI-301, is currently in late-stage trials. The company's stock performance is closely watched by investors in the biotech sector.

The details

The sharp decline in Kodiak's stock price on Monday came amid broader market volatility. Several Wall Street analysts have weighed in on the company's prospects, with UBS Group raising its price target to $80 and reiterating a 'buy' rating, while HC Wainwright boosted its target to $58 and maintained a 'buy' recommendation. However, Weiss Ratings issued a 'sell' rating on the stock.

  • Kodiak Sciences stock closed at $37.00 on the previous trading day.
  • On Monday, the stock traded as low as $34.75 and closed at $34.10.

The players

Kodiak Sciences Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases.

UBS Group

A global financial services firm that raised its price target on Kodiak Sciences to $80 and reiterated a 'buy' rating.

HC Wainwright

An investment bank that boosted its price target on Kodiak Sciences to $58 and maintained a 'buy' recommendation.

Weiss Ratings

A financial research firm that issued a 'sell' rating on Kodiak Sciences stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Kodiak Sciences' stock price volatility reflects the high-risk, high-reward nature of the biotech industry. Investors will be closely watching the progress of the company's lead drug candidate and any updates from Wall Street analysts as they assess the stock's long-term potential.